Literature DB >> 16988505

Association analysis of peroxisome proliferator-activated receptor gamma polymorphisms and late onset Alzheimer's disease in the Finnish population.

Anne M Koivisto1, Seppo Helisalmi, Jussi Pihlajamaki, Mikko Hiltunen, Keijo Koivisto, Leena Moilanen, Johanna Kuusisto, Eeva-Liisa Helkala, Tuomo Hanninen, Kari Kervinen, Y Antero Kesaniemi, Markku Laakso, Hilkka Soininen.   

Abstract

Alzheimer's disease (AD), especially late-onset AD (LOAD), is a complex disease. To date, the only established genetic risk factor for LOAD is apolipoprotein E (APOE) epsilon4, which explains partially the risk of the disease and modifies the age of onset. Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates the transcription of BACE1 as well as inflammatory responses in the brain and atherosclerotic risk factors known to be involved also in AD. Based on these findings, the gene encoding PPARgamma can be viewed as an interesting candidate in AD. We examined the effect of the two previously reported variants of PPARgamma polymorphisms, the Pro12Ala and exon 6 C478T, on the risk of LOAD and age of onset in a population-based follow-up sample of aged subjects (125 LOAD patients and 462 non-demented controls). The genetic risk of AD was not significantly associated with the studied polymorphisms, but the PPARgamma Ala12-478T genotype carriers were significantly younger at the onset of dementia than the non-carriers (p = 0.026). These results suggest that the PPARgamma gene may modify the age of onset in LOAD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988505     DOI: 10.1159/000095857

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  7 in total

1.  The PPAR-gamma Pro12Ala polymorphism and risk of cognitive impairment in a longitudinal study.

Authors:  Nancy A West; Mary N Haan; Hal Morgenstern
Journal:  Neurobiol Aging       Date:  2008-07-17       Impact factor: 4.673

Review 2.  COMT Val158Met and PPARγ Pro12Ala polymorphisms and susceptibility to Alzheimer's disease: a meta-analysis.

Authors:  Young Ho Lee; Gwan Gyu Song
Journal:  Neurol Sci       Date:  2014-01-30       Impact factor: 3.307

3.  Lack of Genetic Associations of PPAR-γ and PGC-1α with Alzheimer's Disease and Parkinson's Disease with Dementia.

Authors:  Nobuto Shibata; Yumiko Motoi; Hiroyuki Tomiyama; Tohru Ohnuma; Bolati Kuerban; Katrin Tomson; Miwa Komatsu; Hiromi Shimazaki; Nobutaka Hattori; Heii Arai
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2013-05-18

4.  Impact and Therapeutic Potential of PPARs in Alzheimer's Disease.

Authors:  Michael T Heneka; Elisabet Reyes-Irisarri; Michael Hüll; Markus P Kummer
Journal:  Curr Neuropharmacol       Date:  2011-12       Impact factor: 7.363

Review 5.  EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease.

Authors:  Vladimir Khavinson; Natalia Linkova; Ekaterina Kozhevnikova; Svetlana Trofimova
Journal:  Molecules       Date:  2020-12-31       Impact factor: 4.411

Review 6.  Effects of bisphenol-A and other endocrine disruptors compared with abnormalities of schizophrenia: an endocrine-disruption theory of schizophrenia.

Authors:  James S Brown
Journal:  Schizophr Bull       Date:  2008-01-31       Impact factor: 9.306

7.  PPARγ2 polymorphism and human health.

Authors:  Weimin He
Journal:  PPAR Res       Date:  2009-04-16       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.